AEOL 10150 is one of a potential new class of disease-modifying compounds based on small molecule catalytic antioxidants being developed by the company. The compound mimics and amplifies the body’s natural enzymatic systems for eliminating free radicals, which are believed to have an important role in the origin and growth of many diseases.
The escalating single-dose study was conducted to evaluate the safety, tolerability and pharmacokinetics of AEOL 10150 administered by subcutaneous injection in patients with Lou Gehrig’s disease.
All six single doses (3, 12, 30, 45, 60 and 75mg) were well-tolerated with no serious adverse events, no significant laboratory abnormalities and no cardiovascular issues related to AEOL 10150.
“We are very pleased with the results from our phase I single dose study of AEOL 10150 and we are looking forward to moving this exciting and potential therapeutic into multiple dose evaluation,” noted Richard Burgoon, Aeolus’ CEO.
According to the company, in addition to efficacy in the scientifically recognized ALS model, AEOL 10150 has also demonstrated efficacy in models of other neurodegenerative disorders, autoimmune diabetes, stroke, chronic obstructive pulmonary disease, pancreatic islet cell preservation, radiation-induced lung fibrosis, and inflammation.